ERBB2 and breast carcinoma: Amplification and overexpression of HER2 (also named ErbB2) receptor tyrosine kinase, detected in 20–30% of breast cancer, are associated with a poor clinical patient outcome, including lymph node metastasis, shorter survival, and shorter time to recurrence [1, 2].